Document:

<PAGE>

                                                                    Exhibit 10.1

                           AMENDED LICENSE AGREEMENT
                           -------------------------

          THIS AGREEMENT ("Agreement") entered into as of the 20th day of
December, 1999 ("Effective Date"), by and between:

Ludwig Institute for Cancer Research, a Swiss not-for profit corporation, having
an office at 605 Third Avenue, New York, New York 10158 ("LICR"); and

Magainin Pharmaceuticals, Inc., a Delaware Corporation having an office at 5110
Campus Drive, Plymouth Meeting, PA 19462 ("MPI").

                                  WITNESSETH
                                  ----------

          WHEREAS, on December 20, 1996, LICR and MPI entered into a license
agreement in relation to the cytokine IL-9 and its receptor (the "Initial
License Agreement") and now desire to revise and amend said agreement in this
"Amended License Agreement;"

          WHEREAS, LICR has granted licenses to Peprotech Inc., Pharmingen,
Genzyme Corporation and R&D Systems to make, use, import, offer to sell and sell
IL-9 and/or its receptors and/or antibodies to IL-9 and its receptor for
research purposes only and to Innogenetics, N.V. for research and diagnostic
purposes only (the "Prior Licenses");

          WHEREAS, LICR has acquired certain IL-9 patent rights from Genetics
Institute, Inc. ("GI") and has granted GI an option to license IL-9 for
therapeutic use (the "GI Option");

          WHEREAS, on December 20, 1996, LICR and MPI entered into a
collaborative research agreement relating to the cytokine IL-9 and its receptor
(the "First Research Agreement") and are concurrently herewith entering into a
new research agreement (the "Second Research Agreement");

          NOW THEREFORE, in consideration of the mutual covenants and conditions
contained herein, and intending to be legally bound, LICR and MPI agree as
follows:

_______________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       1
<PAGE>

                             Part 1 - Definitions
                             --------------------

          1.1  "The Field" shall mean the diagnosis and treatment of atopic
allergies including asthma, bronchial hyperresponsiveness, rhinitis, eczema,
urticaria, conjunctivitis, the inflammatory bowel syndrome and HIV.

          1.2  "Affiliate" shall mean any corporation, company, partnership
and/or firm which controls or is controlled by or is under common control with
MPI. For the purposes of this definition, control shall mean: (a) in the case of
corporate entities, direct or indirect ownership of at least fifty percent (50%)
of the stock or participating shares entitled to vote for the election of
directors; and (b) in the case of non-corporate entities, direct or indirect
ownership of at least fifty percent (50%) of the equity interest or the power to
direct the management and policies of such entity.

          1.3  "LICR Patent Rights" shall mean the patents and patent
applications set forth in Amended Appendix A hereto, any division, continuation
or continuation-in-part of such applications, any patent which shall issue based
on any such application, division, continuation or continuation-in-part and any
reissue or reexamination of any such patent, and any patent applications or
patents corresponding to any such patent application or patent which has been or
hereafter is filed or issued in any country.

          1.4  "Product" shall mean any drug or other product which incorporates
or embodies IL-9 or the IL-9 receptor in any form including fragments thereof,
and/or any drug or other product which invokes, blocks, interferes with,
interacts with, binds to and/or prevents binding to IL-9 or the IL-9 receptor
and/or antibodies to IL-9 and/or the IL-9 receptor, and/or where the making,
using, importing, offering to sell or selling of such drug or other product in
the absence of a right or license, would infringe LICR Patent Rights.

          1.5  "Net Sales" shall mean, with respect to any quantity of Product
subject to royalty under this Agreement that is sold by MPI or any of its
Affiliates or sublicensees to any third party, the gross invoice selling price
for that quantity of Product, less: (a) discounts and allowances to customers,
(b) credits for returned goods, (c) prepaid freight, (d) sales taxes or other
governmental charges paid in connection with the sale; and (e) commissions and
other fees paid to distributors and

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       2
<PAGE>

other sales agencies for or in connection with the sale of Product. In the event
that a Product is sold in combination with another active ingredient or
component having independent therapeutic effect or diagnostic utility, then "Net
Sales," for purposes of determining royalty payments on the combination, shall
be calculated using one of the following methods:

     (a)  By multiplying the Net Sales of the combination by the fraction A/A+B,
          where A is the gross selling price, during the royalty paying period
          in question, of the Product sold separately, and B is the gross
          selling price, during the royalty period in question, of the other
          active ingredients or components sold separately; or

     (b)  In the event that no such separate sales are made of the Product or
          any of the other active ingredients or components in such combination
          package during the royalty paying period in question, Net Sales, for
          the purposes of determining royalty payments, shall be calculated by
          dividing the Net Sales of the combination by the number of active
          ingredients or components (including Products) contained in the
          combination.

                           Part 2 - Confidentiality
                           ------------------------

       2.1  Subject to Part 6.1 of the Second Research Agreement, each party
agrees that during the term of and any subsequent extension of this Agreement,
and for a period of five (5) years thereafter, a party shall not use or disclose
to any third party without the prior written consent of the other party any
Confidential Information. For purposes of this Agreement, "Confidential
Information" means any data or materials which are disclosed or furnished by one
party to the other hereunder and designated in writing as confidential. Oral
disclosures of Confidential Information must be confirmed in writing and
designated confidential within ten (10) days of disclosure.

       2.2  A receiving party shall have no obligation to the disclosing party
with respect to any portion of such Confidential Information which:

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       3
<PAGE>

       (a)   is or later becomes generally available to the public by use,
             publication or the like, through no fault of the receiving party;

       (b)   is obtained from a third party who had the legal right to disclose
             the same to the receiving party; or

       (c)   is already possessed by the receiving party, as evidenced by its
             written records, predating receipt thereof from the disclosing
             party; or

       (d)   is required to be disclosed by the receiving party to file and
             prosecute patent applications, to comply with applicable laws, to
             defend or prosecute litigation or to comply with governmental
             regulations, provided that the receiving party provides prior
             written notice of such disclosure to the other party and takes
             reasonable and lawful actions to avoid and/or minimize the degree
             of such disclosure.

                           Part 3 - Clinical Trials
                           ------------------------

       3.1   (a)  LICR will have the option to undertake the first clinical
trials for therapeutic applications of Product in the field of human cancer upon
terms, conditions (including MPI's financial support for such trials) and
protocols to be mutually agreed by LICR and MPI. Product manufactured according
to GMP for any such trial shall be furnished to LICR by MPI free of charge
provided MPI has elected for other reasons to manufacture such Product. If MPI
is not manufacturing a Product, MPI will assist LICR in having such Product
manufactured by a third party.

             (b)  MPI at its discretion may undertake clinical trials of Product
in the Field.

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       4
<PAGE>

                       Part 4 - Patents and Patent Costs
                       ---------------------------------

       4.1  LICR at its expense shall be responsible for prosecuting and
maintaining patent applications and patents included in LICR Patent Rights set
forth in Amended Appendix A. From and after December 20, 1999, MPI will
reimburse LICR for the [**] included in LICR Patent Rights. The cost of [**]
such patents will be prorated in equal portions among licensees in the event
LICR grants any new licenses for therapeutic use under LICR Patent Rights
outside the Field.

       4.2  Set forth below is an accounting of all patent costs, broken down by
[**], incurred by LICR in respect of LICR Patent Rights set forth in Amended
Appendix A during the period commencing December 20, 1996 and ending December
19, 1999. Such patent costs reimbursed by MPI [**] which LICR will pay MPI
within thirty (30) days after signing of this Amended License Agreement.

<TABLE>
<CAPTION>
                                  [**]              [**]              Other          Total
                                  USD               USD                USD            USD
----------------------------------------------------------------------------------------------
<S>                               <C>               <C>               <C>            <C>
Paid by Magainin                  [**]              [**]              [**]            [**]
(12/20/1996-12/20/1999)
----------------------------------------------------------------------------------------------
Invoiced, unpaid                  [**]              [**]              [**]            [**]
----------------------------------------------------------------------------------------------
Not yet invoiced                  [**]              [**]              [**]            [**]
----------------------------------------------------------------------------------------------
             Total                [**]              [**]              [**]            [**]
----------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------
Paid by Magainin                                    [**]
----------------------------------------------------------------------------------------------
Due to Magainin                                     [**]
----------------------------------------------------------------------------------------------
</TABLE>

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       5
<PAGE>

                            Part 5 - License Grant
                            ----------------------

       5.1  Subject to the Prior Licenses and the GI Option, LICR hereby grants
to MPI, and MPI hereby accepts, an exclusive license to make, have made, use,
sell, offer to sell, and import Product in the Field throughout the world.

       5.2  (a) MPI shall have the right to grant sublicenses to Affiliates and
others with respect to any rights conferred upon MPI under Part 5.1 hereof,
provided, however, that any such sublicense shall be subject in all respects to
the restrictions, exceptions and termination provisions contained in this
Agreement. MPI will promptly notify LICR upon the granting of any such
sublicense including the identity of the sublicensee. Notwithstanding the
foregoing, MPI shall not, without LICR's prior written approval, grant a
sublicense hereunder to any entity whose primary business is in the manufacture
and/or sale of tobacco, cigarettes, cigars, chewing tobacco or other similar
tobacco containing products.

            (b) MPI shall be responsible to LICR for all obligations of its
Affiliates and sublicensees hereunder in the same fashion and to the full extent
that MPI is obligated to LICR hereunder, including, but not limited to, the
payment of royalties due with respect to sales made by Affiliates and
sublicensees, which sales shall be treated as though they were sales by MPI.
Affiliates and sublicensees may pay royalties and provide royalty accountings to
MPI but without prejudice to the ultimate responsibility of MPI to LICR
hereunder. A breach by an Affiliate or sublicensee of MPI will be treated as a
breach by MPI. If LICR is required to bring suit against an Affiliate or a
sublicensee for breach of this Agreement, MPI will pay all costs incurred in
connection therewith, including without limitation attorneys fees and
disbursements provided any Affiliate or sublicensee is held liable for any such
breach.

       5.3  Subject to the license granted to MPI under Part 5.1 hereof, the
Prior Licenses and the GI Option, LICR agrees not to enter into any commercial
arrangement outside the Field with any third party involving LICR Materials,
LICR Technology or LICR Patent Rights without first giving MPI a first option to
same. MPI shall have [**] days from the date of written notification by LICR to
exercise such option in writing. If MPI exercises its option the parties will
negotiate in good faith to conclude a license agreement. If the parties are
unable to conclude a

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       6
<PAGE>

license within [**] of MPI exercising said option, LICR shall be free to license
outside the Field.

                              Part 6 - Royalties
                              ------------------

       6.1  For the licenses granted to MPI for Product under Part 5.1 hereof,
and Parts 2.2 and 3.1 of the Second Research Agreement, MPI shall pay LICR as
follows:

            (a) A running royalty of [**] based on the Net Sales by MPI, its
sublicensees or Affiliates of all Product manufactured, imported, offered for
sale, sold or used by MPI, its Affiliates or sublicensees.

            (b) Commencing on the termination of the Second Research Program and
any extensions thereof as defined by Part 4.1 of the Second Research Agreement
(the "Termination Date"), an annual license maintenance fee of [**], payable on
the Termination Date and each successive anniversary of the Termination Date
thereafter until MPI, an Affiliate or sublicensee commences selling a Product.
Annual license maintenance fees paid by MPI hereunder may be credited by MPI
against royalties earned hereunder in excess of the minimal annual royalty of
Part 6.1(c) hereof.

            (c) A minimum annual royalty of [**] payable on a deficiency basis
ninety (90) days after each anniversary of the Effective Date after MPI, an
Affiliate or sublicensee commences selling a Product in respect of royalties
paid hereunder during the twelve (12) month period preceding each anniversary of
the Effective Date. If royalties are paid hereunder for less than twelve (12)
months prior to the anniversary of the Effective Date, the minimum royalty for
such shortened period shall be pro rated.

            (d) [**] of all proceeds from sublicensing Product but excluding
royalties and reimbursement to MPI for research and development costs in the
Field.

       6.2  (a) Royalty payments required to be made by MPI to LICR shall be
made in U.S. Dollars within sixty (60) days following the end of each calendar

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       7
<PAGE>

quarter. Each such payment shall include the royalties which shall have accrued
during the calendar quarter immediately preceding and shall be accompanied by a
report certified by MPI's chief financial officer setting forth separately the
Net Sales of all Product sold during said calendar quarter.

          (b)  Royalties shall be payable only once with respect to the same
unit of Product regardless of the number of claims of LICR Patent Rights
pertaining to same. Royalties shall become payable at the time of any sale or
transfer of Product by MPI, its Affiliates and sublicensees to the user thereof.
If MPI sells Product in bulk form for repackaging and sale to the ultimate user,
royalties will become payable upon such sale to the end user and not upon the
sale of Product in bulk form.

          (c)  The remittance of royalties payable on Net Sales outside the U.S.
shall be made to LICR notwithstanding currency restrictions or regulations in
any country where Product is sold and in U.S. Dollars at the official rate of
exchange of the currency of the country from which the royalties are payable (as
quoted by Citibank N.A. for the last business day of the calendar quarter in
which the royalties are payable) less any withholding or transfer taxes which
are applicable. MPI shall supply LICR with proof of payment of such taxes paid
on LICR's behalf and shall cooperate with LICR in obtaining credit or refund of
any such taxes.

          (d)  MPI and its Affiliates and sublicensees shall keep and maintain
records of sales of Product. Such records shall be open to inspection at any
reasonable time during normal business hours not more often than once each
calendar quarter within three (3) years after the royalty period to which such
records relate by an independent Certified Public Accountant selected by LICR,
to whom MPI or its Affiliates or sublicensees have no reasonable objection, who
shall have the right to examine and make abstracts of the records kept pursuant
to this Agreement and report findings of said examination of records to LICR
insofar as it is necessary to evidence any mistake or impropriety on the part of
MPI. Said public accountant shall treat as confidential and shall not disclose
to LICR any information other than information which shall be given to LICR
pursuant to any provision of this Agreement.

          (e)  MPI's obligation to pay royalties shall continue on a country-by-
country basis for so long as LICR shall own an issued patent in any

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       8
<PAGE>

country under LICR Patent Rights or until [**] years from the first sale of
Product by MPI, its Affiliates or sublicensees, whichever shall later occur.

                         Part 7 - Patent Infringement
                         ----------------------------

       7.1  In the event that LICR or MPI determines that a third party may be
infringing a claim of a patent within LICR Patent Rights, it will so notify the
other party in writing. MPI shall have the first right as its expense to
institute and control all actions brought for infringement of any claim of any
licensed patent within LICR Patent Rights provided such infringement is within
the Field. Such actions may be brought, whenever in MPI's sole judgment such
actions may be necessary, proper or justified. MPI will give LICR sixty (60)
days prior written notice of its intent to commence such an action and identify
the potential infringer and the basis of the action. From any monetary award in
such action, MPI shall retain the balance, after MPI first recovers its
reasonable expenses in prosecuting the suit, and second, after MPI pays to LICR
a sum equal to the royalties LICR would have received had the infringing
products been subject to the terms of this Agreement. If, within the period of
one hundred and twenty days (120) following notification to MPI by LICR of a
third party infringement of LICR Patent Rights within the Field, MPI is unable
or unwilling to sue such alleged infringer and has not notified LICR in writing
of its intent to promptly commence an action to terminate the alleged
infringement, LICR shall have the right to commence such action at its own
expense, in which case LICR shall retain any monetary award in such action. LICR
shall have the sole right at its expense to institute and control all actions
brought for infringement of any claim of any patent under LICR Patent Rights,
where such infringement is outside the Field.

       7.2  In the event any party shall initiate or carry on legal proceedings
to enforce any patent within LICR Patent Rights against an alleged infringer,
the other party shall fully cooperate with, and supply all reasonable assistance
requested by the party initiating or carrying on such proceedings. Neither party
shall compromise or settle any claim or action regarding any patent under LICR
Patent Rights in any manner that would affect the rights of the other party
without the written consent of said other party, which consent shall not be
unreasonably withheld.

       7.3  In the event that MPI, an Affiliate or a sublicensee is sued by a
third party charging infringement of a patent resulting from the manufacture,
use, or sale

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       9
<PAGE>

by MPI, or an Affiliate or sublicensee of a Product covered by LICR Patent
Rights, MPI shall promptly notify LICR. During the period in which any such suit
is pending, MPI shall have the right to apply up to fifty percent (50%) of the
royalties due LICR against MPI's litigation expenses of any such suit or against
royalties paid by MPI to a third party in settlement of such litigation.

                              Part 8 - Diligence
                              ------------------

       8.1  MPI agrees to use reasonable efforts to effect introduction of
Product in the Field into the commercial market as soon as practicable,
consistent with sound and reasonable business practices and judgment. To this
end, within ninety (90) days after MPI identifies a Commercial Product
Opportunity (as defined below) for a Product in the Field, MPI shall submit a
proposal to LICR for developing and marketing the Product. Such plan would
include development and marketing efforts no less strenuous than MPI uses for
the development and marketing of its own products.

       8.2  "Commercial Product Opportunity" shall mean demonstration of the
efficacy of a Product for a specific therapeutic application in the Field either
by data collected from an FDA Phase 1 trial or by other evidence clearly
establishing efficacy.

                    Part 9 - Indemnification and Insurance
                    --------------------------------------

       9.1  MPI agrees to defend, indemnify and hold LICR and its agents
harmless from any claims, demands, suits or causes of action, including all
judgments, damages, and costs (including reasonable attorneys' fees) resulting
therefrom, arising out of the use, manufacture, sale, storage or advertising of
any Product.

       9.2  At least sixty (60) days before MPI first begins using any Product
in humans, including in human clinical trials, MPI shall obtain and maintain
thereafter a comprehensive general liability insurance policy (to include
advertisers liability and product liability) written by a reputable insurer or
insurers and shall list LICR as an additional named insured thereunder and shall
require thirty (30) days written notice to be given to LICR prior to any
cancellation or material change thereof. The limits of such insurance for
personal injury and property damage shall not be less than [**] for any Phase I
clinical trial of any Product [**]

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       10
<PAGE>

for any later phase clinical trial of any Product and [**] upon approval to sell
Product anywhere. MPI shall provide LICR with certificates of insurance
evidencing the same.

                     Part 10 - Term and Early Termination
                     ------------------------------------

       10.1  Unless sooner terminated as herein provided, this Agreement shall
continue in full force and effect commencing with the Effective date of this
Agreement and continuing until [**] years from the first sale of Product by MPI,
its Affiliates or sublicensee or until the expiration of the last-to-expire
patent in LICR Patent Rights, whichever shall later occur.

       10.2  Either party may terminate this Agreement and the license herein
granted upon the breach of any of the terms herein contained by either party
upon sixty (60) days written notice; provided that if during said sixty (60)
days the party so notified cures the breach complained of then this Agreement
shall continue in full force and effect.

       10.3  In the event this Agreement shall be terminated as provided in Part
10.2, MPI shall promptly make an accounting to LICR of the inventory of Product
which it and its Affiliates and sublicensees have on hand as of the date of such
termination. MPI, its Affiliates and sublicensees shall then have the right, for
a period of [**] after said termination, to sell such inventory provided that
the Net Sales thereof shall be subject to the royalty rates set forth above and
so payable to LICR.

       10.4  In the event that further lawful performance of this Agreement or
any part hereof by either party shall be rendered impossible by or as a
consequence of any law, regulation, order, rule, direction, priority, seizure,
allocation, requisition, or any other official action by any department, bureau,
board, administration or other instrumentality or agency or any government or
political subdivision thereof having jurisdiction over such party, such party
shall not be considered in default hereunder by reason of any failure to perform
occasioned thereby.

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       11
<PAGE>

                         Part 11 - General Provisions
                         ----------------------------

       11.1  Except as required by law, and, in the case of LICR, except as may
be required in order to maintain its status as an exempt organization under Sec.
501(c)(3) of the U.S. Internal Revenue Code and regulations thereunder, neither
LICR nor MPI shall originate any publicity, news release, or other public
announcement, written or oral, whether to the public press, to stockholders, or
otherwise, relating to this Agreement to any amendment thereto or to performance
hereunder or the existence of an arrangement between the parties without the
prior written approval of the other party. MPI shall not use the name of the
Ludwig Institute for Cancer Research (or any variant thereof) or any related
organization in any advertising, packaging (except for customary technical
references) or other promotional material in connection with the sale of Product
pursuant to this Agreement.

       11.2  MPI acknowledges that it has certain duties and obligations under
Part 379 of the Export Administration Regulations of the U.S. Department of
Commerce (as presently promulgated or hereafter modified or amended) concerning
the export and reexport of technical data. MPI will be solely responsible for
any breach of such Regulations by MPI, its Affiliates or sublicensees and will
defend and hold LICR harmless in the event of a suit or action involving LICR
occasioned by any such breach.

       11.3  Neither party shall unreasonably withhold its consent or agreement
when such consent or agreement is required hereunder or is requested in good
faith by the other party hereunder.

       11.4  This Agreement is unassignable by either party except with the
prior written consent of the other and except that it may be assigned without
consent to a corporate successor of MPI or LICR or to a person or corporation
acquiring all or substantially all of the business and assets of the division or
divisions of MPI involved in the development and sale of Product.
Notwithstanding the foregoing LICR may assign its rights hereunder to a
corporate affiliate, division or successor and MPI may assign its rights
hereunder to an Affiliate which may be substituted directly for MPI hereunder.

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       12
<PAGE>

       11.5  Notice hereunder shall be deemed sufficient if given by telefax and
registered mail, postage prepaid, and addressed to the party to receive such
notice at the address given herein, or such other address as may hereinafter be
designated by notice in writing. All such notices shall be considered as given
when telefaxed and mailed as aforesaid:

To LICR:          Ludwig Institute for Cancer Research
                  605 Third Avenue
                  New York, New York 10158

                  Facsimile No. (212) 450-1555

                  Attn: Lloyd J. Old, M.D.
                  Chief Executive Officer

with copies to:   Ludwig Institute for Cancer Research
                  605 Third Avenue
                  New York, New York 10158

                  Facsimile No. (212) 450-1555

                  Attn: Edward A. McDermott, Jr.
                  President
and
                  London Office
                  Ludwig Institute for Cancer Research
                  6th Floor Glen House
                  Stag Place
                  London SW1E 5AG, England

                  Facsimile No. 44171 8285427

                  Attn: Prof. A. Munro Neville
                  Associate Director

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       13
<PAGE>

To MPI:           Magainin Pharmaceuticals, Inc.
                  5110 Campus Drive
                  Plymouth Meeting, PA 19462

                  Facsimile No. (610) 941-5399

                  Attn: Roy C. Levitt, M.D.
                  President and Chief Executive Officer

     11.6    None of the terms of this Agreement may be waived or modified
except by an express agreement in writing signed by the party against whom
enforcement of such waiver or modification is sought.

     11.7    Each party represents and warrants that it has to the best of its
knowledge and will have the full right, power and authority to enter into this
Agreement and to disclose and to deliver all of the information delivered to the
other pursuant to this Agreement and to grant the licenses and rights granted
therein.

     11.8    This Amended License Agreement replaces and supersedes the Initial
License Agreement. This Amended License Agreement thus contains the entire
understanding of the parties hereto with respect to the subject matter herein
contained and will control in the event of any conflict with the Initial License
Agreement.

     11.9    This Agreement shall be construed and enforced under the laws of
New York.

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       14
<PAGE>

       IN WITNESS WHEREOF, the parties hereto have caused this instrument to be
executed by their respective duly authorized officers or representatives on the
respective dates indicated below.

THE LUDWIG INSTITUTE FOR CANCER RESEARCH

By   /s/ Lloyd J. Old, M.D.
  -------------------------
     Lloyd J. Old, M.D.
     Chief Executive Officer

By   /s/ Edward A. McDermott, Jr.
  -------------------------------
     Edward A. McDermott, Jr.
     President

  MAGAININ PHARMACEUTICALS, INC.

  By   /s/ Roy C. Levitt, M.D.
    --------------------------
       Roy C. Levitt, M.D.
       President and Chief Executive Officer

__________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       15<PAGE>

                                                                    EXHIBIT 10.2

                           SECOND RESEARCH AGREEMENT

          THIS AGREEMENT ("Agreement") entered into as of the 20th day of
December, 1999 ("Effective Date"), by and between:

Ludwig Institute for Cancer Research, a Swiss not-for profit corporation, having
an office at 605 Third Avenue, New York, New York 10158 ("LICR"); and

Magainin Pharmaceuticals, Inc., a Delaware Corporation having an office at 5110
Campus Drive, Plymouth Meeting, PA 19462 ("MPI").

                                  WITNESSETH
                                  ----------

       WHEREAS, on December 20, 1996, LICR and MPI entered into a collaborative
research agreement relating to the cytokine IL-9 (the "First Research Agreement"
or the "FRP Agreement") and now desire to:

       i.    allocate the right to exploit Joint Materials, Joint Technology and
             Joint Patent Rights created and jointly owned by LICR and MPI
             pursuant to the First Research Agreement; and

       ii.   establish a new collaborative effort upon the terms and conditions
             set forth herein, the present agreement being referred to as the
             "Second Research Agreement;" and

       WHEREAS, on December 20, 1996, LICR and MPI entered into a license
agreement relating to IL-9, its receptors and related reagents (the "Initial
License Agreement") and are concurrently herewith entering into an amendment
license agreement (the "Amended License Agreement."

       NOW THEREFORE, in consideration of the mutual covenants and conditions
contained herein, and intending to be legally bound, LICR and MPI agree as
follows:

____________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.
<PAGE>

                             Part 1 - Definitions
                             --------------------

       1.1   The "First Research Program" or "FRP" shall mean the program of
research carried out by LICR and MPI under the First Research Agreement.

       1.2   The "Second Research Program"  or "SRP" shall mean the program of
research set forth in Appendix A attached hereto.

       1.3   "LICR Materials" shall mean the materials, animals or reagents
furnished or to be furnished to MPI by LICR under the First Research Agreement
and/or hereunder and all progeny, proteins, peptides, recombinant constructs,
plasmids, cultures, subcultures and mutations of or derived from the foregoing.

       1.4   "MPI Materials" shall mean the materials, animals or reagents
furnished or to be furnished to LICR by MPI under the First Research Agreement
and/or hereunder and all progeny, proteins, peptides, recombinant constructs,
plasmids, cultures, subcultures and mutations of or derived from the foregoing.

       1.5   "FRP Joint Materials" shall mean  Joint Materials produced or
discovered as a result of the FRP as defined by Part 1.4 of the First Research
Agreement.  FRP Joint Materials are documented in final reports of the First
Research Program by LICR and MPI attached hereto as Appendices B and C,
respectively.

       1.6   "SRP Joint Materials" shall include but not be limited to all
proteins, peptides, ligands, new drugs, small molecules, cell lines, polyclonal
and monoclonal antibodies, protein and peptide sequences or segments, assay
reagents, transgenic animals and the like produced or discovered during the term
of and as a result of the Second Research Program.  LICR Materials, MPI
Materials and FRP Joint Materials are excluded from the definition of SRP Joint
Materials.

       1.7   "LICR Technology" shall mean all data, discoveries, inventions,
technical information and know-how relating to LICR Materials and disclosed to
MPI under the First Research Agreement and/or hereunder by LICR.

____________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       2
<PAGE>

       1.8   "MPI Technology" shall mean all data, discoveries, inventions,
technical information and know-how relating to MPI Materials and disclosed under
the First Research Agreement and/or hereunder to LICR by MPI.

       1.9   "FRP Joint Technology" shall mean Joint Technology made, granted or
discovered as a result of the FRP as defined by Part 1.7 of the First Research
Agreement.

       1.10  "SRP Joint Technology" shall mean all data, discoveries,
inventions, technical information and know-how relating to the Second Research
Program made, generated or discovered during the term of and as a result of the
Second Research Program by either party individually or jointly with the other
party hereto and whether or not using LICR Materials or MPI Materials. LICR
Technology, MPI Technology and FRP Joint Technology are excluded from the
definition of SRP Joint Technology.

       1.11  "LICR Patent Rights" shall mean the patents and patent applications
set forth in Appendix D hereto, any division, continuation or continuation-in-
part of such applications, any patent which shall issue based on any such
application, division, continuation or continuation-in-part and any reissue or
reexamination of any such patent, and any patent applications or patents
corresponding to any such patent application or patent which has been or
hereafter is filed or issued in any country.

       1.12  "MPI FRP Patent Rights" shall mean the U.S. patent applications set
forth in Appendix E1 attached hereto, and any division, continuation and
continuation-in-part of any such applications, any patent which shall issue
based on any such application, division, continuation, and continuation-in-part
and any reissue of any such patent, and any patent applications or patents
corresponding to any such patent application or patent which has been or
hereafter is filed or issued in any country.

       1.13  "LICR FRP Patent Rights" shall mean the U.S. patent applications
set forth in Appendix E2 attached hereto, and any division, continuation and
continuation-in-part of any such applications, any patent which shall issue
based on any such application, division, continuation, and continuation-in-part
and any reissue of any such patent, and any patent applications or patents
corresponding to any such

____________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       3
<PAGE>

patent application or patent which has been or hereafter is filed or issued in
any country.

       1.14  "SRP Joint Patent Rights" shall mean any patent application
covering SRP Joint Materials and/or SRP Joint Technology, any division,
continuation and continuation-in-part of any such applications, any patent which
shall issue based on any such application, division, continuation, and
continuation-in-part and any reissue of any such patent, and any patent
applications or patents corresponding to any such patent application or patent
which has been or hereafter is filed or issued in any country.  MPI FRP Patent
Rights and LICR FRP Patent Rights are excluded from the definition of SRP Joint
Patent Rights.

       1.15  "MPI FRP Rights" shall collectively mean MPI FRP Patent Rights, FRP
Joint Materials and FRP Joint Technology relating thereto.

       1.16  "LICR FRP Rights" shall collectively mean LICR FRP Patent Rights,
FRP Joint Materials and FRP Joint Technology relating thereto.

       1.17  "SRP Joint Rights" shall collectively mean SRP Joint Materials, SRP
Joint Technology and SRP Joint Patent Rights.

       1.18  "Affiliate" shall mean any corporation, company, partnership and/or
firm which controls or is controlled by or is under common control with MPI.
For the purposes of this definition, control shall mean: (a) in the case of
corporate entities, direct or indirect ownership of at least fifty percent (50%)
of the stock or participating shares entitled to vote for the election of
directors; and (b) in the case of non-corporate entities, direct or indirect
ownership of at least fifty percent (50%) of the equity interest or the power to
direct the management and policies of such entity.

       1.19  The "Field" shall mean the diagnosis and treatment of atopic
allergies including asthma, bronchial hyperresponsiveness, rhinitis, eczema,
urticaria, conjunctivitis, the inflammatory bowel syndrome and  HIV.

       1.20  "FRP Net Sales" shall mean the gross invoice selling price for any
quantity of any product and/or material included within MPI FRP Rights or LICR
FRP Rights less:  (a) discounts and allowances to customers, (b) credits for
returned goods,

____________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       4
<PAGE>

(c) prepaid freight, (d) sales taxes or other governmental charges paid in
connection with the sale; and (e) commissions and other fees paid to
distributors and other sales agencies for or in connection with the sale of such
product and/or material.  In the event that such product and/or material is sold
in combination with another active ingredient or component having independent
therapeutic effect or diagnostic utility, then "Net Sales," for purposes of
determining royalty payments on the combination, shall be calculated using one
of the following methods:

     (a)  By multiplying the Net Sales of the combination by the fraction A/A+B,
          where A is the gross selling price, during the royalty paying period
          in question, of such product and/or material sold separately, and B is
          the gross selling price, during the royalty period in question, of the
          other active ingredients or components sold separately; or

     (b)  In the event that no such separate sales are made of such product
          and/or material or any of the other active ingredients or components
          in such combination package during the royalty paying period in
          question, Net Sales, for the purposes of determining royalty payments,
          shall be calculated by dividing the Net Sales of the combination by
          the number of active ingredients or components (including such product
          and/or material) contained in the combination.

                               Part 2 - Licenses
                               -----------------

          2.1  Subject to licenses granted by each party to the other hereunder,
LICR and MPI will each own an undivided, equal interest in  MPI FRP Rights and
LICR FRP Rights.

          2.2  LICR hereby grants MPI a world-wide exclusive license, with the
right to grant sublicenses, to make, have made, use, sell, offer to sell and
import products, materials and methods included within MPI FRP Rights.

          2.3  Subject to the license granted to MPI in respect of Product in
the Field under Part 5.1 of the Amended License Agreement, MPI hereby grants
LICR a

____________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       5
<PAGE>

world-wide exclusive license, with the right to grant sublicenses, to make, have
made, use, sell, offer to sell or import products, materials and methods
included within LICR FRP Rights subject to the rights reserved below. The
parties acknowledge that MPI has entered into a License and Collaboration
Agreement with Genentech to develop and commercialize certain products for the
treatment of IL-9 related disorders, pursuant to which LICR shall not include
subject matter falling within Product or Field as defined in the Amended License
Agreement.

          2.4  MPI and LICR shall each have the sole right to exploit MPI FRP
Rights and LICR FRP Rights, respectively, in any manner each so chooses subject
only to an obligation by each party to pay the other a royalty of [**] of FRP
Net Sales by a party and/or its Affiliates and sublicensees and [**] of proceeds
received by either party in respect of exploiting or licensing MPI FRP Rights or
LICR FRP Rights, as the case may be.  Such proceeds will include option and
licensing fees and milestone payments and the like but shall exclude royalties
and research funding paid to either party to support research relating to MPI
FRP Rights or LICR FRP Rights as the case may be.  MPI's royalty obligation
under this Part 2.4 does not preclude the payment of royalties under the Amended
License Agreement, if applicable, in respect of MPI FRP Rights.

          2.5  (a)  Sublicenses granted by either party hereunder shall be
subject in all respects to the restrictions, exceptions and termination
provisions contained in this Agreement.  Each party will promptly notify the
other upon the granting of any such sublicense including the identity of the
sublicensee.  Notwithstanding the foregoing, MPI shall not, without LICR's prior
written approval, grant a sublicense hereunder to any entity whose primary
business is the manufacture and/or sale of tobacco, cigarettes, cigars, chewing
tobacco or other similar tobacco containing products.

               (b)  Each party shall be responsible to the other for all
obligations of its Affiliates and sublicensees hereunder in the same fashion and
to the full extent that each party is obligated to the other hereunder,
including, but not limited to, the payment of royalties due with respect to
sales made by Affiliates and sublicensees, which sales shall be treated as
though they were sales by MPI or LICR. Affiliates and sublicensees may pay
royalties and provide royalty accountings to a party but without prejudice to
the ultimate responsibility of MPI or LICR hereunder. A breach by an Affiliate
or sublicensee of a party will be treated as a breach by that party. If a party

____________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       6
<PAGE>

is required to bring suit against an Affiliate or a sublicensee for breach of
this Agreement, the other party will pay all costs incurred in connection
therewith, including without limitation attorneys fees and disbursements,
provided any Affiliate or sublicensee is held liable for any such breach.

          2.6  (a)  Royalty payments required to be made by MPI to LICR, or by
LICR to MPI, shall be made in U.S. Dollars within ninety (90) days following the
end of each calendar quarter.  Each such payment shall include the royalties
which shall have accrued during the calendar quarter immediately preceding and
shall be accompanied by a report certified by the paying party's chief financial
officer setting forth separately the FRP Net Sales for said calendar quarter.

               (b)  Royalties shall be payable only once regardless of the
number of claims of MPI FRP Patent Rights or LICR FRP Patent Rights pertaining
to the product sold. Royalties shall become payable at the time of any sale or
transfer by either party, its Affiliates and sublicensees to the user thereof.
If either party sells product in bulk form for repackaging and sale to the
ultimate user, royalties will become payable upon such sale to the end user and
not upon the sale of product in bulk form.

               (c)  The remittance of royalties payable on Net Sales outside the
U.S. shall be made notwithstanding currency restrictions or regulations in any
country where product is sold and in U.S. Dollars at the official rate of
exchange of the currency of the country from which the royalties are payable (as
quoted by Citibank N.A. for the last business day of the calendar quarter in
which the royalties are payable) less any withholding or transfer taxes which
are applicable. Each party shall supply the other with proof of payment of such
taxes paid on the other's behalf and shall cooperate with such party in
obtaining credit or refund of any such taxes.

               (d)  Each party and its Affiliates and sublicensees shall keep
and maintain records of FRP Net Sales. Such records shall be open to inspection
at any reasonable time during normal business hours not more often than once
each calendar quarter within three (3) years after the royalty period to which
such records relate by an independent Certified Public Accountant selected by
one party, to whom the other party or its Affiliates or sublicensees have no
reasonable objection, who shall have the right to examine and make abstracts of
the records kept pursuant to this Agreement and

____________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       7
<PAGE>

report findings of said examination of records insofar as it is necessary to
evidence any mistake or impropriety on the part of a party hereunder. Said
public accountant shall treat as confidential and shall not disclose to LICR any
information other than information which shall be given to LICR pursuant to any
provision of this Agreement.

               (e)  Each party's obligation to pay royalties shall continue on a
country-by-country basis for so long as MPI and LICR shall own an issued patent
in any country under LICR FRP Patent Rights or MPI FRP Patent Rights or until
[**] years from the first sale of Product by MPI, LICR, or their Affiliates or
sublicensees, whichever shall later occur.

          2.7  Each party will provide the other with an annual report by April
1 of each year setting forth proceeds received under Part 2.4 hereof, if any,
during the preceding calendar year, together with any payment due the other
hereunder for any such year.  Provided it is free to do so, each party will
provide the other with copies of agreements entered into in respect of MPI FRP
Rights and LICR FRP Rights, as the case may be.

                              Part 3 - SRP Rights
                              -------------------

          3.1  LICR and MPI will each own an undivided equal interest in SRP
Joint Materials, SRP Joint Technology and SRP Joint Patent Rights.  Except for
the license granted to MPI under the Amended License Agreement, and to the
extent that any new drugs or products resulting from the SRP are not Products as
defined by Part 1.3 of the Amended License Agreement but are otherwise embodied
by SRP Joint Materials, SRP Joint Technology and/or SRP Joint Patent Rights,
neither LICR nor MPI will license or commercially exploit SRP Joint Materials,
SRP Joint Technology and/or SRP Joint Patent Rights without the prior written
consent of the other party and subject to terms and conditions to be mutually
agreed to in writing.

                     Part 4 - Research Program and Reports
                     -------------------------------------

          4.1  (a)  LICR and MPI will provide each other with LICR Materials,
MPI Materials, FRP Joint Materials and SRP Joint Materials, and will disclose
LICR Technology, SRP Joint Technology and MPI Technology, as are reasonably
necessary

____________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       8
<PAGE>

for the parties hereto to carry out their respective portions of the Second
Research Program.

               (b)  Each party will keep a log of LICR Materials, MPI Materials,
FRP Joint Materials and SRP Joint Materials sent or received under this
Agreement and the FRP Agreement. Each party's log will be updated every six (6)
months and a copy furnished to each party pursuant to Part 12.4 hereof. Except
as provided herein, such Materials and Technology will be used solely for
carrying out the Second Research Program and will not be furnished or disclosed
by either party hereto to any third party without the prior written consent of
the other party.

               (c)  Notwithstanding paragraph (b) above, LICR may furnish FRP
and SRP Joint Materials developed by or at LICR, and MPI may furnish FRP and SRP
Joint Materials developed by or at MPI, to educational or research institutions
for non-commercial research purposes only, pursuant to a material transfer
agreement in the form attached as Appendix F. LICR and MPI will require any
recipient to acknowledge in any publication LICR and/or MPI as the source of a
Material.

               (d)  Notwithstanding paragraph (b) above, and only to the extent
that they comprise Product as defined by Part 1.4 of the Amended License
Agreement and/or information necessary to make and/or use Product, MPI may
furnish and/or disclose LICR Materials, LICR Technology, FRP Joint Materials,
FRP Joint Technology, SRP Joint Materials and/or SRP Joint Technology to
prospective sublicensees or sublicensees granted rights under Part 5.2(a) of the
Amended License Agreement, provided, however, any such sublicensee or
prospective sublicensee is bound to the same extent MPI is bound hereunder in
respect of the use and confidentiality of such Materials and/or Technology. MPI
will promptly notify LICR in writing upon furnishing and/or disclosing such
Materials and/or Technology to any sublicensee or prospective sublicensee.

          4.2  (a)  The Brussels Branch of LICR and MPI shall undertake the
Research Program as described in Appendix A over a period of two (2) years from
December 20, 1999.  LICR and MPI may, but are not obligated to,  extend the
Second Research Program as mutually agreed in writing.  Each party will notify
the other in writing within ten (10) days of entering into any academic
collaboration in respect of the Second Research Program.

____________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       9
<PAGE>

               (b)  Representatives of the Brussels Branch of LICR, LICR
Administration and MPI shall meet from time to time as mutually agreed to
discuss and review the progress of the Second Research Program and changes
therein to be mutually agreed to in writing within thirty (30) days following
any such meeting. The London office of LICR will be advised prior to any such
meeting. The Parties will exchange written copies of their presentations at the
meetings and jointly agree as to any changes within thirty (30) days. Copies of
these presentations will be lodged with MPI and the London office of LICR within
sixty (60) days after each meeting. Discussions outside the scope of the SRP at
any such meeting shall be excluded from SRP Joint Rights provided the disclosing
party notifies the other party of same in writing within thirty (30) days of
such meeting.

               (c)  LICR and MPI agree that LICR's portion of the Second
Research Program shall be supervised by Dr. Jean-Christophe Renauld of the
Brussels Branch of LICR and MPI's portion shall be supervised by Dr. Roy Levitt
of MPI. Either party may propose a substitute for any of the foregoing
scientists subject to mutual agreement between the parties hereto.

          4.3  Each party agrees to furnish the other party with a final written
report summarizing the results of its Second Research Program within sixty (60)
days of completion of its Second Research Program. Either party may designate
any portion of any report provided pursuant to this Part 3.3 or Part 3.2(b)
hereof as Confidential Information as defined in Part 5 hereof.

                            Part 5 - Funding by MPI
                            -----------------------

          5.1  In partial support of the cost of the Second Research Program to
be undertaken by LICR as set forth in Appendix A, MPI shall make the following
payments to LICR:

          Payment Date                  Payment Due
          ------------                  -----------
          January 1, 2000               [**]
          July 1, 2000                  [**]
          January 1, 2001               [**]
          July 1, 2001                  [**]

____________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       10
<PAGE>

     The above payments shall be adjusted by increases in the annual salary
costs in accordance with the Belgian Salary Index (Indice Sante) and laboratory
costs and overhead in accordance with the Belgian Consumer Price Index (Indice
Complet) based on December 1999.

          5.2  All payments pursuant to this Agreement shall be made by credit
transfer to LICR's bank account as follows:

Beneficiary/Payee:   Ludwig Institute for Cancer Research

Account No.:         [**]

With:                [**]

Clearing:            [**]
SWIFT:               [**]

                           Part 6 - Confidentiality
                           ------------------------

          6.1  In developing the Second Research Program, data and results will
be disclosed by each party in confidence to each other. Each party agrees that
during the term of, and during any subsequent extension of this Second Research
Agreement, and for a period of five (5) years thereafter, each party shall not
use or disclose any Confidential Information to any third party without the
prior written consent of the other party. For purposes of this Agreement,
"Confidential Information" means all LICR Materials, MPI Materials, LICR
Technology, MPI Technology, FRP Materials, FRP Joint Technology, SRP Joint
Materials and SRP Joint Technology which are disclosed or furnished by one party
to the other under the First Research Agreement and/or hereunder and designated
in writing as confidential. Oral disclosures of Confidential Information must be
confirmed in writing and designated confidential within ten (10) days of
disclosure. Either party may disclose Confidential Information to collaborators,
potential collaborators, licensees, potential licensees, sublicensees and
potential sublicensees provided, however, each such recipient of Confidential
Information is bound in confidence in writing to the disclosing party at least
to the

________________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       11
<PAGE>

same extent that party is bound to the other party hereunder.  Each party will
furnish the other with copies of all confidentiality agreements entered into
with a collaborator or potential collaborator, together with a description of
the subject matter disclosed or to be disclosed.

          6.2  A receiving party shall have no obligation to the disclosing
party with respect to any portion of such Confidential Information which:

               (a)  is or later becomes generally available to the public by
use, publication or the like, through no fault of the receiving party;

               (b)  is obtained from a third party who had the legal right to
disclose the same to the receiving party; or

               (c)  is already possessed by the receiving party, as evidenced by
its written records, predating receipt thereof from the disclosing party; or

               (d)  is required to be disclosed by the receiving party to file
and prosecute patent applications, to comply with applicable laws, to defend or
prosecute litigation or to comply with governmental regulations, provided that
the receiving party provides prior written notice of such disclosure to the
other party and takes reasonable and lawful actions to avoid and/or minimize the
degree of such disclosure.

                       Part 7 - Patents and Patent Costs
                       ---------------------------------

          7.1  LICR and MPI shall consult and agree on the filing of U.S. and
international patent applications covering SRP Joint Materials or SRP Joint
Technology.  MPI shall have the responsibility of filing, prosecuting and
maintaining patent applications and patents included in SRP Joint Patent Rights
and shall provide LICR with copies of all Patent Office correspondence in all
patent applications included in SRP Joint Patent Rights in sufficient time to
provide comments.  Each party will provide the other with Patent Office
correspondence in respect of LICR Patent Rights, SRP Joint Patent Rights and FRP
Joint Patent Rights, as the case may be, in sufficient time to provide comments.
The party responsible for handling such patent rights will provide the other
with a status report in writing by facsimile on or about March 15 and September
15 of each year starting with 2001.

________________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       12
<PAGE>

          7.2  From and after the Effective Date of the FRP Agreement, each
party will be responsible for patent costs associated with their respective MPI
FRP Rights and LICR FRP Rights. Within thirty (30) days of the Effective Date,
the parties will exchange accountings of all patent costs incurred by each party
in respect of MPI FRP Rights and LICR FRP Rights which will then be adjusted and
paid in accordance with the allocations made under Parts 1.12 and 1.13 hereof.

          7.3  MPI will be responsible for all patent costs associated with SRP
Joint Patent Rights.

                             Part 8 - Publications
                             ---------------------

          8.1  Each party recognizes that the other party may wish to disclose
the results of the First and Second Research Programs in the form of
presentations at scientific meetings or publications in scientific journals.
Each party agrees to submit in writing all such proposed presentations or
publications, whether written or oral, to the other party fifteen (15) days
prior to submitting same for presentation or publication to enable the parties
to take appropriate patent action.

                         Part 9 - Patent Infringement
                         ----------------------------

          9.1  In the event that LICR or MPI determines that a third party may
be infringing a claim of a patent within SRP Joint Patent Rights, it will so
notify the other party in writing. MPI shall have the right at its expense to
institute and control all actions brought for infringement of SRP Joint Patent
Rights. All recoveries in any such suit shall be shared equally between LICR and
MPI after deducting MPI's out-of-pocket expenses (including attorney fees)
incurred by MPI as the result of any such action. LICR shall have the right but
not the obligation to bring suit at its expense for infringement of SRP Joint
Patent Rights in the event MPI fails to bring suit within one hundred twenty
(120) days of any such notice. All recoveries in any such suit shall inure to
LICR. MPI and LICR shall each have the exclusive rights, but not the obligation,
to enforce their respective MPI FRP Patent Rights and LICR FRP Patent Rights and
retain all recoveries therefrom.

          9.2  In the event any party shall initiate or carry on legal
proceedings under Part 9.1 hereof, the other party shall fully cooperate with,
and supply all

________________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       13
<PAGE>

reasonable assistance requested by the party initiating or carrying on such
proceedings.  Neither party shall compromise or settle any claim or action under
Part 9.1 hereof in any manner that would affect the rights of the other party
without the written consent of said other party, which consent shall not be
unreasonably withheld.

                           Part 10 - Indemnification
                           -------------------------

          10.1  LICR Materials, MPI Materials, FRP Joint Materials, SRP Joint
Materials, LICR Technology, MPI Technology, FRP Joint Technology and SRP Joint
Technology are being provided to and accepted by each party  WITHOUT ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OR ANY OTHER
WARRANTY, EXPRESS OR IMPLIED.  Each party, and its directors, officers,
employees, or agents assume no liability and make no representation in
connection with its Materials and Technology, including FRP and SRP Joint
Materials and FRP and SRP Joint Technology, or their use by any other party.  No
representation is made as to the testing of any reagent provided for the
presence or absence of any pathogens in any reagent and each party assumes all
risk of harm with respect to any such pathogens.

                     Part 11 - Term and Early Termination
                     ------------------------------------

          11.1  Unless sooner terminated as herein provided, this Second
Research Agreement shall continue in full force and effect commencing with the
Effective Date and continuing until the expiration of the last-to-expire patent
in MPI FRP Patent Rights, LICR FRP Patent Rights or SRP Joint Patent Rights.

          11.2  Either party may terminate this Second Research Agreement and
the license herein granted upon the breach of any of the terms herein contained
by either party upon sixty (60) days written notice; provided that if during
said sixty (60) days the party so notified cures the breach complained of then
this Second Research Agreement shall continue in full force and effect. If a
breach complained of involves the payment of money hereunder by either party,
the cure period will be shortened to thirty (30) days. Parts 5, 6 and 7 hereof
will remain in full force and effect and survive any termination of this Second
Research Agreement.

________________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       14
<PAGE>

          11.3  In the event that further lawful performance of this Second
Research Agreement or any part hereof by either party shall be rendered
impossible by or as a consequence of any law, regulation, order, rule,
direction, priority, seizure, allocation, requisition, or any other official
action by any department, bureau, board, administration or other instrumentality
or agency or any government or political subdivision thereof having jurisdiction
over such party, such party shall not be considered in default hereunder by
reason of any failure to perform occasioned thereby.

                         Part 12 - General Provisions
                         ----------------------------

          12.1  Except as required by law, and, in the case of LICR, except as
may be required in order to maintain its status as an exempt organization under
Sec. 501(c)(3) of the U.S. Internal Revenue Code and regulations thereunder,
neither LICR nor MPI shall originate any publicity, news release, or other
public announcement, written or oral, whether to the public press, to
stockholders, or otherwise, relating to this Second Research Agreement to any
amendment thereto or to performance hereunder or the existence of an arrangement
between the parties without the prior written approval of the other party.

          12.2  Neither party shall unreasonably withhold its consent or
agreement when such consent or agreement is required hereunder or is requested
in good faith by the other party hereunder.

          12.3  This Second Research Agreement is unassignable by either party
except with the prior written consent of the other and except that it may be
assigned without consent to a corporate successor of MPI or LICR or to a person
or corporation acquiring all or substantially all of the business and assets of
the division or divisions of MPI.  Notwithstanding the foregoing LICR may assign
its rights hereunder to a corporate affiliate, division or successor and MPI may
assign its rights hereunder to an Affiliate which may be substituted directly
for MPI hereunder.

          12.4  Notice hereunder shall be deemed sufficient if given by telefax
and registered mail, postage prepaid, and addressed to the party to receive such
notice at the address given herein, or such other address as may hereinafter be
designated by notice in writing. All such notices shall be considered as given
when telefaxed and mailed as aforesaid:

________________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       15
<PAGE>

To LICR:          Ludwig Institute for Cancer Research
                  605 Third Avenue
                  New York, New York 10158

                  Facsimile No. (212) 450-1555

                  Attn: Lloyd J. Old, M.D.
                  Chief Executive Officer

with copies to:   Ludwig Institute for Cancer Research
                  605 Third Avenue
                  New York, New York 10158

                  Facsimile No. (212) 450-1555

                  Attn: Edward A. McDermott, Jr.
                  President
and
                  London Office
                  Ludwig Institute for Cancer Research
                  6th Floor Glen House
                  Stag Place
                  London SW1E 5AG, England

                  Facsimile No. 44171 8285427

                  Attn: Prof. A. Munro Neville
                  Associate Director

________________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       16
<PAGE>

To MPI:           Magainin Pharmaceuticals, Inc.
                  5110 Campus Drive
                  Plymouth Meeting, PA 19462

                  Facsimile No. (610) 941-5399

                  Attn: Roy C. Levitt, M.D.
                  President and Chief Executive Officer

          12.5  None of the terms of this Second Research Agreement may be
waived or modified except by an express agreement in writing signed by the party
against whom enforcement of such waiver or modification is sought.

          12.6  Each party represents and warrants that it has to the best of
its knowledge and will have the full right, power and authority to enter into
this Second Research Agreement and to disclose and to deliver all of the
information delivered to the other pursuant to this Agreement and to grant the
licenses and rights granted therein.

          12.7  The First Research Agreement is hereby superseded and replaced
by this Second Research Agreement. This Second Research Agreement thus contains
the entire understanding of the parties hereto with respect to the subject
matter herein contained and will control in the event of any conflict with the
First Research Agreement.

          12.8  This Second Research Agreement shall be construed and enforced
under the laws of New York.

________________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       17
<PAGE>

       IN WITNESS WHEREOF, the parties hereto have caused this instrument to be
executed by their respective duly authorized officers or representatives on the
respective dates indicated below.

THE LUDWIG INSTITUTE FOR CANCER RESEARCH

By /s/ Lloyd J. Old, M.D.
  -----------------------
    Lloyd J. Old, M.D.
    Chief Executive Officer

By /s/ Edward A. McDermott, Jr.
  -----------------------------
    Edward A. McDermott, Jr.
    President

   MAGAININ PHARMACEUTICALS, INC.

   By /s/ Roy C. Levitt, M.D.
    ----------------------------------------
      Roy C. Levitt, M.D.
      President and Chief Executive Officer

________________________

** Certain portions of this exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                       18
<PAGE>

APPENDIX A        Second Research Program

APPENDIX B        LICR First Research Program Final Report

APPENDIX C        MPI First Research Program Final Report

APPENDIX D        LICR Patent Rights

APPENDIX E1/E2    Allocation of FRP Joint Patent Rights

APPENDIX F        Material Transfer Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]